INTRODUCTION
The goal of the original three-year proposal was to gain insight into the roles of mitochondrial energy metabolism and oxidative stress in the etiology of neuronal degeneration in Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). The development of mutant mouse lines (expressing human mutant transgenes or mutations m mouse homologues), that mimic aspects of human diseases, provide novel opportunities to assess the temporal progression of pathological changes over the course of disease development in an in vivo animal model. Experiments aimed to determine the relative contributions and sequential order of bioenergetic dysfunction and oxidative damage to cell death processes in two different mutant mouse models of HD (Hdh knock-in mice; R6/2 mice) and one transgenic (Tg) mouse model of familial ALS (G93A SODl over-expressors) (White et al, 1997; Mangiarini et al., 1996; Gumey et al., 1994) . We found that one of these mouse Unes (R6/2 HD mice) develop a diabetic profile that interfered with cerebral glucose use assays. This necessitated substituting another transgenic line that similarly expresses a fragment of mutant human huntingtin (N171-82Q mice; Schilling et al., 1999) in some experiments. The use of mitochondrial toxins also allows us to model in animals the cerebral pathogenic sequelae induced by naturally occurring agents that are potentially extremely hazardous to humans. Further studies in this proposal used 3-nitropropionic acid , a toxin that produces brain lesions and symptoms in humans resembling those seen in HD following systemic exposure. In 2002, this proposal was extended by the addition of a second project, subtitled "Mitochondrial Free Radical Generation In Parkinson's Disease". This project continues the theme of investigating the interactions between energy metabolism and oxidative stress in the etiology of neurodegenerative disorders, and is a sub-project of a Consortium of investigators. The aims of this project are to try to ascertain in vivo whether inhibition of a component of the mitochondrial respiratory chain (complex I), implicated in the pathogenesis of Parkinson's disease (PD), induces pathogenesis via free radical generation, and whether the mitochondria are the initial source of these free radicals. These are questions that are somewhat easier to address by in vitro approaches (as in other Consortium projects), given the extreme technical difficulties of discretely measuring purely mitochondrial events in vivo. Therefore we are taking an indirect approach, by measuring the time-course and nature of oxidative events caused by toxic insults directed specifically against mitochondrial molecules. Results may give insight into sites for drug targeting in PD.
The original Specific Aims for the five years of study are: Year 1; October 1998 -September 1999 1) a) Measurement of local rates of cerebral glucose use GCMRgic) in Hdh knock-in mice expressing CAG repeat lengths found in HD patients (48 CAG repeats, Hdh^^°) , relative to ICMRgic in wild type littermates (7 CAG repeats, Hdh^'') . b) Assessment of any gene dosage effect: Homozygous vs. heterozygous animals. 2) Measurement of electron transport chain activities in Hdh knock-in mice with disease-length and normal-length CAG repeats.
Principal Investigator: S.E. Browne, Ph.D 3) Measurement of ICMRgjc in the G93A Tg mouse model of ALS overexpressing human mutant SODl. Analysis of the temporal progression of ICMRgic changes, at 50,90 and 120d of age. 4) Measurement of electron transport chain enzyme activities in G93A ALS mice at 60 and 120d. Hospital, Boston, MA, to Weill Medical College of Cornell University in New York, NY. This resulted in a delay in funding during grant transferal (September 1999 to August 2000 , and in re-establishing mutant mouse colonies in the New York. brain regions at time points after administration of subunit-specific complex I inhibitors to rats: (i) Stereotactic unilateral intracerebral injection of rotenone, DCCD, or pyridaben into the region of the substantia nigra of anesthetized rats; and vehicle into the contraleteral hemisphere. Rats will be sacrificed and brain tissue harvested at multiple time-points post-injection (Ih, 6h, 24h, 7d) . (ii) Spectrophotometric measurement of complex I activity, citrate synthase activity (a marker for mitochondrial number), and protein levels in post-mortem tissue from the striatum, nigra, cortex and cerebellum.
A^^; The laboratory moved from Massachussetts General
14) Commence characterization of the regional and temporal development of cerebral oxidative damage after administration of rotenone, DCCD and pyridaben to rats. (i) HPLC measurement of oxidative damage markers at time-points before and after complex inhibition (time-points and regions determined in 1) by: HPLC detection of brain levels of DNA damage product 8-hydroxy-deoxyguanosine (8-OHdG), (ii) HPLC and immunohistochemical detection of lipid peroxidation marker malondialdehyde in affected brain regions. 15) Assessment of levels of free radical markers in striatal ECF microdialysates before and after inhibiting sub-unit activity, at time-points elucidated in (i), by: (i) HPLC detection of hydroxyl (OH) radical levels in microdialysate samples from striatum; by measuring the extent of conversion of salicylate (i.p. injection) to DHBA by OH, DHBA detected in dialysate. (ii) HPLC detection of microdialysate levels of DNA damage product 8-hydroxy-deoxyguanosine ; and (iii) Immunocytochemical localization of 8-OHdG throughout brains of inhibitor-treated rats. 11; and (ii) First year of the Consortium SOW ("Year 4" -NB: an incomplete SOW period is covered by this report period).
BODY

A. Overview of Original Proposal Project
The pathogenetic mechanisms in both Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS) are still unclear, however, in both cases in vivo and in vitro studies implicate the involvement of bioenergetic defects in the disease process (for review see Browne and Beal, 2000; Menzies et al., 2002) . Attempts to ascertain the role of energetic dysfunction in pathogenesis have been greatly enhanced by the development of several different transgenic mouse lines replicating aspects of each disorder. HD models express the huntingtin gene mutation underlying HD, an abnormal expansion of the polyglutamine (Q) domain in huntingtin protein, encoded by an expanded triplet (CAG) repeat in exon 1 of the huntingtin gene. Familial ALS (FALS) models express some of the multiple Cu/Zn superoxide dysmutase (SOD-1) mutations that occur in approximately 25% of familial ALS patients. These models allow novel determinations of metaboUc parameters over the lifespan of the animals, before, during and after onset of pathological changes and disease symptoms.
HD mouse Unes differ in terms of the site of mutant gene incorporation, CAG repeat length, copy number, and promoter used, and these differences are reflected in the phenotypes of the mice generated. Studies in this project utilize Hdh CAG knock-in mice (White et al., 1997) , R6/2 transgenic mice overexpressing an N-terminal fragment of human mutant huntingtin, including a 145 polyglutamine repeat stretch (Mangiarini et al., 1996) , and N171-82Q mice also expressing an Nterminal fragment of human mutant huntingtin, but with a shorter (82Q) polyglutamine repeat stretch (Schilling et al., 1999) . The ALS mouse model employed is the G93A model (Gumey et al., 1994) , overexpressig a human SOD-1 glycine to alanine mutation. Studies utilized both in vivo and in vitro experimental approaches in mutant mice and in rats, to investigate parameters of cerebral energy metaboUsm (in vivo cerebral glucose use measurement by [**C]-2-deoxyglucose autoradiography; NMR lactate imaging; in vitro spectrophotometric oxidative phosphorylation enzyme assays; HPLC detection of metabolites), and to investigate the generation of DNA and protein oxidative damage products, and free radical generation (HPLC detection; immunohistochemistry).
Studies in the first three years of this grant generated several exciting novel observations of presymptomatic energetic abnormalities in both HD and ALS models. Firstly, we found that cerebral glucose utilization is markedly elevated in the forebrain of mice expressing the HD mutation. Most interestingly, this hypermetaboUsm occurs prior to any evidence of pathologic changes or symptoms in these animals. Further, we have recapitulated this observation in two distinctly different HD mutant mouse models: Hdh^^^ "knock-in" mice expressing a mutant expansion of the disease-causing CAG repeat in the murine homologue HD gene (92 CAGs) (White et al., 1997) ; and N171-82Q mice expressing a fragment of human huntingtin gene containing a mutant CAG repeat length (82 CAGs) (Schilling et al., 1999 , and experimental or environmental exposure to an agent that specifically inhibits this enzyme (3-NP) produces pathological lesions and phenotypic changes similar to HD (Ludolph et al., 1992) . In studies in the rat, we found striatal neurons to be selectively vubierable to 3-NP toxicity despite widespread complex II inhibition throughout the brain. However, in contrast to presymptomatic changes in genetic models, significant reductions in glucose use following 3-NP intoxication coincided with neuronal loss in this mouse line. Therapeutic approaches using pro-energy agents such as creatine have been shown (in other studies) to be neuroprotective in this lesion model . We believe this model provides a useful approach for further elucidation of regional vutaerability in HD. In another mouse model of a neurodegenerative disorder, the G93A mouse model of familial ALS (overexpressing human mutant Cu/Zn superoxide dismutase, SOD-1), we also found a pattem of early metabolic changes that precede the first observations of neuronal pathology (mitochondrial disruption at -70 days) and symptom onset (-100 days). Studies revealed reduced glucose utilization in brain and spinal cord at 60 days of age, concomitant with increased mitochondrial complex I activity in these mice. Further, depletions in brain and spinal cord ATP levels were evident as early as 30 days of age. Elevated free radical generation is also evident in the cortex by 90 days (earliest time-point examined to date). In this fALS model, cells appear to have reduced capacity for glucose uptake before symptom onset, but the rate of complex I activity is elevated, perhaps in an attempt to increase electron transport and boost falling ATP production.
Results in mutant mouse models of both ALS and HD clearly demonstrate the early involvement of metabolic changes in the sequence of events initiated by expression of the mutant disease gene, prior to pathologic changes, symptom onset and cell death. The nature of the metabolic changes seen differs between the HD and ALS models, suggesting that the nature of triggering events set in motion by the gene defect may vary in these disorders. While it still remains to elucidate the exact pathway from 
The finding of impaired activities of complexes II-III and IV of the electron transport chain in
Hdh^^'^and Hdh^^^ mouse brain cerebellum at 4 months of age (preceding symptom onset and Nil formation).
3. The finding that aconitase activity is increased in the cerebellum of Hdh^^" (48/48) mice at 4 months of age.
4. The finding tiiat cerebral glucose use is reduced in several forebrain regions in tiie G93A tiransgenic mouse model of FALS at 60 days of age -a time point preceding the onset of the first pathological changes in these mice.
5. The finding of increased complex I activity in tiie forebrain of G93A mice at 60 days of age, indicating impaired mitochondrial energy metaboUsm consistent with the defect seen in FALS A4V patients with a SODl mutation, which precedes onset of symptoms and pathological changes.
YEAR 2:
6. The finding tiiat cerebral glucose use is significantiy increased in Hdh°^^ CAG knock-in mice at 4 months of age, relative to levels in wild type animals, and relative to levels in Hdh9^°imce (Year 1 results). , 2000) . It is possible that use of whole brain homogenate preparations is masking any subfle region-specific changes occur, for example in tiie striatiun of R6/2 mouse brains. Therefore we are currently repeating tiiese assays in striatal preparations from these mice.
YEAR 3:
12. The finding of increased lactate production in symptomatic HD mice, suggesting abnormal energy metabolism at this stage of the disorder in R6/2 mice. This is consistent with lactate elevations seen in symptomatic HD patients.
13. Increases in multiple oxidative damage markers (0H8dG, hydroxyl radical, F2 isoprostaglandins, and hydroxynonenol) in symptomatic R6/2 and N171-82Q HD mouse models.
14. Findings of increased oxidative damage to protein (carbonyl detection), but not lipid (malondialdehyde) in tiie G93A ALS model. Earhest effects occurred in symptomatic mice (llOd).
15. The finding of reduced ATP levels in R6/2 HD mouse forebrain, and to a lesser extent in cerebellum 16 . The observation that cerebral glucose utilization in striatum does not appear to be significanfly altered prior to lesion formation induced by 3-NP administration (in rats).
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Principal Investigator: S.E. Browne, Ph.D
B. Overview of Consortium Proposal Project
The overall goals of the studies in this grant are to gain insight into the roles of mitochondrial by MPTP/MPP+ or rotenone) in the brain can result in region-specific neuropathologic changes resembling PD. In vitro studies implicate mitochondria as a major source of free radicals mediating oxidative damage and pinpoint a number of the >40 complex I subunits as candidate sites for fi-eeradical production. An important step in understanding the mechanism of region-specific cell damage in PD is to determine in vivo whether there is a direct link between abnormal mitochondrial function and the generation of ROS in the disease. We aim to approach this question by manipulating the activities of different complex I subunits within mitochondria, using intracerebral delivery of subunit-specific complex I inhibitors in rats. Markers of free radical generation will then be measured in vivo by microdialysis, and in post-mortem tissue. We intend to test inhibitors with different specificities for the NDl (mitochondrially encoded) and PSST subunits of complex I. By this approach we will determine if selectively altering functional components of mitochondrial complex I affects complex I activity and free radical generation. By limiting the intervention to a mitochondrial component, and by measuring ROS production shortly after the mitochondrial insult, we will ascertain if generated ROS derive from mitochondria rather than other cellular origins.
NADH-ubiquinone oxido-reductase (complex I) is the first and largest enzyme complex of the mitochondrial respiratory chain. The overall function of complex I is to ti^ansfer one pair of electrons from NADH to flavin mono-nucleotide (FMN), and ultimately to ubiquinone (UQ), whilst simultaneously pumping hydrogen ions out of the mitochondrial matiix into the inter-membrane space.
Complex I has a molecular mass of approximately 900-10110 kDa and comprises at least 43 subunits (Triepels et al., 2001 ), 7 of which are encoded by mitochondrial (mt) DNA (ND1-ND6, ND4L), and the remainder by nuclear (n) DNA. Subunits are organised into an L-shape structure, consisting of a hydrophobic membrane arm embedded into the inner mitochondrial membrane (MM) and a hydrophilic peripheral ami aligned perpendicular to the IMM and directed into the mitochondrial matrix. The peripheral arm is comprised of 2 fractions; a flavoprotein (FP) where electron transfer begins, and iron-sulphur (Fe-S) clusters (N), several of which act as redox groups that facilitate electron transfer. Binding sites for NADH and FMN are found on the peripheral arm. The membrane arm is comprised of at least 24 nDNA-encoded subunits , the 7 mtDNA subunits, and possibly two Fe-S clusters (Okun et al., 1999) .
The electron carrier NADH enables entry of electrons into complex I. There are two well defined binding sites for NADH in eukaryotes, 51kDa and 39kDa subunits. It is believed that 39kDa subunit is required to maintain stability of the redox group X and thus facilitate electron transfer (Schulte et al., 2001 ). Electron input occurs via the FMN prosthetic group together with Fe-S clusters (Rasmussen et al., 2001 ). The 'catalytic core' of complex one is comprised of the PSST, TYKY, NUOD, NDl and ND5 subunits (Schuler et al., 2001) . PSST is a 23-kDa subunit containing one binding site for Fe-S cluster N2. It plays a vital role in electron transfer by functionally coupling N2 to CoQ (Schuler et al., 1999) . The binding of CoQ is the final stage in electron transfer via complex I and an important function of the membrane arm. The actual quinone binding site has not been equivocally proven, and different studies suggest it is encoded by the NDl and ND4 proteins (Triepels et al., 2001) , or a hydrophilic 49-lcDa/NUOD subunit located at the interface of the peripheral and membrane arms (Darrouzet et al., 1998) . The TYKY subunit is proposed to bind two tetranuclear Fe-S clusters (N6a and N6b) that form the novel redox groups found in complex I. TYKY is part of a special class of 8Fe-ferredoxins and works as an electrical driving unit for the proton pump (Rasmussen et al., 2001 ).
The original Consortium project SOW cited using rotenone (NDl and PSST affinities), pyridaben (PSST subunit specific), and dicyclohexylcarbodiimide (DCCD; NDl subunit specific) to selectively inhibit complex I subunit function. However, it has been necessary to make some modifications to this aim in the first year of study. Due to the extreme toxicity of DCCD to humans, combined with its ease of systemic penetration (via skin, eyes, inhalation etc), and the nature of the survival animal experiments employed in this study (facilitating exposure to potentially toxic animal excretions), we deemed it unsafe for experimenters to be exposed to this agent under normal laboratory conditions. Therefore we are currently concentrating on studies utilizing rotenone and pyridaben. While there is some overlap in the targets of these inhibitors in terms of complex I binding sites, rotenone shows greater specificity for the NDl subunit, and pyridaben for the PSST subunit (Schuler et al., 1999) . We have recently obtained a third complex I inhibitor for use in these studies, Piericidin A (the kind gift of Dr. Thorsten Friedrich, Albert-Ludwigs-Universitaet, Freiberg Germany). Whilst previous studies suggest that piericidin A also binds within the large complex I pocket for CoQ binding, with some overlap with the rotenone binding site (Okun et al., 1999) , a recent study suggests that the two agents differentially affect semiquinone function, and therefore may have distinct binding domains (Magnitsky et al., 2002) . Piericidin A is structurally similar to CoQ and appears to prevent CoQ reduction by dehydrogenase in both complexes I and n (succinoxidase). The sensitivity of complex I for piericidin A is however much greater than complex U, with complete inhibition at 0.036 nmole/mg of mitochondrial protein (Magnitsky et al., 2002) . This observation highlights another potential problem inherent to all studies using compex I inhibitors -namely that they are not completely selective for only complex I. We aim to circumvent this problem by comparing and contrasting the effects of multiple different complex I inhibitors. 
C. Experimental Results
(i) Measurement of Cerebral Metabolite Levels in HD Mouse Brains
R6/2 Mice: HPLC was used to measure levels of the energy metabolites ATP, ADP, AMP, creatine and phosphocreatine in brain tissue in brain tissue of R6/2 HD mice at 4 weeks of age (presymptomatic), 7 weeks of age (onset of initial symptoms of disease; tremor and weight loss), and 12 weeks of age (symptomatic; reduced weight, atrophy of striatum and striatal neurons, tremor, impaired motor performance on a rotarod apparatus). Results were compared with levels in wild-type Uttermates. Metabolite levels in cerebral cortex, striatum and cerebellum of 12 week and 7 week-old mice are presented in Tables 1 and 2 .
Results demonstrate that by 12 weeks of age, towards end-stage of their short lifespans (13-17 weeks), ATP levels in the cortex of R6/2 mice are markedly reduced (~3-fold), relative to levels in wild-type mice (Table 1 ). In contrast, levels of all other metabolites measured were significantly increased in the cerebral cortex. In the cerebellum, metabolite fluctuations resembled those in the cortex, but only changes in creatine and phosphocreatine (PCr) reached statistical significance. In the striatum, phosphocreatine (PCr) levels were similarly significantly increased, but creatine, AMP and ADP levels reduced. ATP levels showed a trend towards decrease in R6/2 striatum, relative to levels in wildtypes. In 7 week-old mice on the verge of symptom onset, few alterations in metabolite levels were evident (Table 2) . PCr again showed a significant elevation in cortex, and trends to increase in the other regions. ADP was significantly reduced in striatum. No other alterations were detected. In younger, 4 week-old presymptomatic mice (n= 6-8 per group), no significant alterations in any parameter were detected (data not shown).
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Principal Investigator: S.E. Browne, Ph.D Metabolite levels (lunol/mg protein, mean ± SEM) in 12 week-old R6/2 mice, and littermate wild-type (Wt) controls. *p< 0.05, ** p< 0.001, significant difference relative toWt levels (Student's unpaired t-test). Metabolite levels (nmol/mg protein, mean ± SEM) in 7 week-old R6/2 mice, and littermate wild-type (Wt) controls. *p< 0.05, significant difference relative to Wt levels (Student's unpaired t-test).
Discussion: Results suggest that generation of ATP is hindered in the cortex of symptomaticl2-week old R6/2 mice. Elevations in cellular levels of AMP and ADP may reflect an inability to generate ATP in cells, leading to a build up of precursors. Increases in levels of other metabolites, phosphocreatine and creatine, may implicate that at this late stage in the disorder, cells are using altemative energy sources. Alternatively, energy demand in this region may be reduced. Further studies are required to determine the significance of these increases in creatine and phosphocreatine. Metabolite alterations are less clear cut in striatum -an intriguing observation, given that the striatum is the primary site of metaboUc alterations and cell loss in HD. However, this discrepancy may be in part due to the mouse model utilized, since the R6/2 mice show little evidence of actual cell loss or other metabolic alterations in the striatum (although mitochondrial morphological changes have been reported, Yu et al., 2003) .
Also, there is mounting evidence that fiinctional alterations in cortical neurons may play a role in inducing alterations in the striatum in HD; thus cortical metabolic changes may precede striatal alterations in this model. These results add to existing evidence of the involvement of metabolic defects in the disease pathogenesis in mutant mouse models. (NB: It has not been possible to measure glucose use in R6/2 mice, due to their diabetic status).
(ii) Hdh Mice: We are currently conducting similar assays in presymptomatic (4 month old) and symptomatic (18 month-old) Hdh9"'Tmce (results have been delayed due to the long period required to breed mice and age them to 18 months). However, in the interim we have conducted studies assessing mitochondrial ATP synthesis and oxygen consumption (Respiratory Control Ratios, RCR), in freshly extracted forebrain mitochondria from 4 month-old Hdh°^"imce. This time-point coincides with the age at which we previously detected significant increases in cerebral glucose utilization in forebrain cortical regions and striatum in these mice (reported in years 2 and 3 of grant). Experiments used the Clark Oxygraph apparatus with glutamate/malate substrate for respiratory rate calculations, and the luciferase-luciferin electrode apparatus for ATP synthesis (Manfredi et al., 2002) .
Results demonstrate a slight trend towards reduced respiratory control ratio in homozygote
Hdh^"'Tmce, compared with wildtype Hdh^^'iaice (Hdh^'" = 7.9 ± 1.5, Hdh^'° = 9.3 ± 1.1; mean ± SEM, n= 7/group). However, ATP synthesis was slightly elevated in the Hdh9'"rmce (Hdh^'" = 376 ± 38 nmol ATP/min/mg/protein, Hdh°^°= 305 ± 25 nmol ATP/min/mg/protein; mean ± SEM, n= 7/group; p = 0.14, unpaired t-test). The small magnitude increase in ATP synthesis is perhaps consistent with the increased uptake of the energy substrate glucose in the brain of these mice at 4 months of age, putatively required to overcome an energetic stress. Studies are currently being extended to older animals. Original Research Goals: 13) Characterization of the regional and temporal development of complex I inhibition in specific brain regions at time points after administration of subunit-specific complex I inhibitors to rats: (i) Stereotactic unilateral intracerebral injection of rotenone, DCCD, or pyridaben into the region of the substantia nigra of anesthetized rats; and vehicle into the contraleteral hemisphere. Rats will be sacrificed and brain tissue harvested at multiple time-points post-injection (Ih, 6h, 24h, 7d). (ii) Spectrophotometric measurement of complex I activity, citrate synthase activity (a marker for mitochondrial nimiber), and protein levels in post-mortem tissue from the striatum, nigra, cortex and cerebellum.
2) Mitochondrial Free Radical Generation In
14) Commence characterization of the regional and temporal development of cerebral oxidative damage after administration of rotenone, DCCD and pyridaben to rats. (i) HPLC measurement of oxidative damage markers at time-points before and after complex inhibition (time-points and regions determined in 1) by: HPLC detection of brain levels of DNA damage product 8-hydroxy-deoxyguanosine (8-OHdG), (ii) HPLC and immunohistochemical detection of lipid peroxidation marker malondialdehyde in affected brain regions. 
Results
Objective 13:
The first requirement of this aim was to find an optimal dosing regime for the inhibitors to be tested. We have commenced studies with rotenone and pyridaben. Rotenone induces selective degeneration in dopaminergic nigro-striatal projections following systemic administration (either intravenous via the jugular veing, sub-cutaneous injection, or intraperitoneal) (Betarbet et al., 2000; Alam and Schmidt et al., 2002 , Sherer et al., 2003 , AntkiewiczMichaluket al., 2003 . These effects are associated with widespread decreases in complex I activity throughout the brain (HogUnger et al., 2003) , but require chronic low dose administration paradigms for generation of these selective lesions (Antkiewicz-Michaluk et al., 2003) . In this study we want to identify oxidative damage paradigms as soon after the complex I inhibition is induced as possible, to try to localize these events to the mitochondria, rather than measuring the downstream repercussions of long-term energetic compromise affecting ROS production in other cellular compartments. Therefore we opted for a direct intracerebral injection administration paradigm for the complex I inhibitors.
All experiments utilize male Lewis rats, 250-300g at the commencement of studies. For stereotactic drug injection into the brain, rats are anestiietized with a cocktail of ketamine (lOOmg/kg) and xylazine (lOmg/kg). Rats are placed in a Kopf stereotactic frame, and body temperature maintained at 37 °C by means of a heating pad.
(i) Dose-response Curve for Rotenone; Complex I Inhibition 1 hour Post-injection
A dose range of 6,20 and 60 jomol rotenone was selected for the initial experiments, based on reported effective doses in studies using other routes of administration. Rotenone (6, 20, 60 pmol) or vehicle (DMSO/polyeihylene glycol cocktail) was injected bilaterally into the striata of rats (3\3l volume, injected over 10 min, plus 5 min lag time before needle is removed; n=4-5/group). After one hour animals were sacrificed by Na-pentobarbital overdose. The striata, cortex and cerebellum were dissected from the brain and rapidly frozen on dry ice. Mitochondrial extracts were prepared firom brain regions by repeated centrifugation and exposure to a percoll
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Principal Investigator: S.E. Browne, Ph.D gradient (modification of Lai and Clark, 1979) . Complex I activity was measured in cortex and striatal mitochondria by spectrophotometric assay of the rate of oxidation of NADH at 340nm (Hatefi, 1978) . Values were corrected for protein content, determined by the method of Bradford (1976) , and for variable amounts of mitochondria in the assay preparations, by measuring activity of the mitochondrial matrix enzyme citrate synthase (rate of oxidation of DTTNB at 412nm; Shepherd and Garland, 1969) . Results for striatal tissue are demonstrated in Figure 1 . Doses of 20 and 60 fimol rotenone produced 25% reductions in complex I activity in the striatum (compared with levels in vehicle-treated rats, p>0.05). The level of complex I inhibition induced by rotenone was more pronounced in the cortex, shown in Table 3 . It is postulated that this effect (which was greater than that anticipated) may be due to back-flow of rotenone up the needle tract. Alternatively, it may reflect transport back to cortex via cortico-striatal nerve terminals, although this seems unlikely given the relatively short period following rotenone injection (Ih). (ii) Time Course of Rotenone Effects; Complex I inhibition We were dissatisfied with the magnitude of complex I inhibition in the striatum following 60fmiol rotenone injection, and therefore conducted pilot experiments with a higher dose, 120fmiol. This dose produced an approximate 3 fold reduction in complex I activity in mitochondrial prearations from striatum, in pilot studies assessing effects at 0, 2,4, 8 and 24h pst-injection. Therefore we chose to use this dose in subsequent experiments. Experiments were expanded to larger group sizes, and results are shown in Figure 2 . Complex I activity was not markedly altered up to 4 hours postinjection, but showed a reduction at 8 and 24 hours post-injection. Ongoing Experiments For Objective 13, and problems encountered: (a) We are currently analyzing data from experiments using an altemative route of rotenone administration, namely intracerebroventricular administration, in an attempt to rapidly generate striatal lesions without inducing the mechanical damage inherent with stereotactic injections. (b) We have encountered many problems with the variability of complex I measurements using the spectrophotometric assay approach. This has proved to be extremely time consuming, and tissue consuming, and is also prone to problems associated with rapid and accurate dissection of brain regions. Therefore we have performed further dose-response studies with rotenone, cut brains into coronal cryostat sections, and are currently processing these sections for histochemical and autoradiographic assessments of complex I activity^ according to the methods of Jung et al. (2002) and Higgins and Greenamyre (1996) , respectively. (c) We are concurrently running experiments elucidating optimum dosing regimes for pyridaben.
Experiments are at the stage of measuring complex I, protein and citrate synthase activities/levels. (d) Cerebellar tissue from each experiment has been dissected and stored. We will analyze cerebellar tissue only from experiments yielding reportable complex I alterations in the striatum (lesion target). Nigral tissue could not be accurately and rapidly dissected from the rats (and is also of less interest since the injection site has been changed to the striatum), however we will be able to detect any complex I changes in this region using the histochemical and autoradiographic approaches.
Objective 14.
(This goal is to be carried out over both years of the consortium project). The research goals of this objective were to use HPLC and immunohistochemical approaches to characterize the nature of any oxidative damage arising after intra-striatal inhibitor injections, and to assess the time course of oxidative damage.
(i) Oxidative Damage Markers After Rotenone Administration HPLC Studies: We have conmienced these studies after rotenone administration in rats. Tissue has been collected from rats that received bilateral injections of rotenone (6,20,60 120 pmol) or vehicle (1 hour post-injection), and at 0,2,4, 8 and 24 h post 120|jmol rotenone. Tissue from striatum, cortex and cerebellum is currently being processed for HPLC assessment of 8-hydroxydeoxyguanosine (OHSdG, DNA damage marker) and malondialdehyde (Upid peroxidative damage marker).
Immunohistochemical Studies:
We have completed assessment of the effects of rotenone insult on levels of the Upid peroxidation markers malondialdehyde and 8-iso-prostaglandin F2, and on the oxidative sfress response marker heme oxygenase. Experiments used immunohistochemical approaches at 8h and 24h after rotenone administration. Heme oxygenase-1 is a member of the stressresponse protein superfamily that catalyzes the rate-limiting step in heme degradation in brain and other tissues. We used a marker for inducible hemeoxygenase, HO-1. The HO-1 gene contains a heat shock element in its promoter region and is rapidly induced upon exposure to heme, metal ions, sulfhydryl compounds, UV light, and various pro-oxidants. Its metabolic products (carbon monoxide and bilirubin) have been shown to exert potent antioxidant and anti-inflammatory activities, and thus the HO pathway is a fundamental defensive mechanism for neurons exposed to an oxidant challenge.
In the brain, astrocytes strongly express HO-1 in response to injury (Gonzales et al., 2002) .
Rotenone (120(jmol in 3nl) was unilaterally injected into one striatum in rats (as previously described), and vehicle (DMSO/PEG) into the contralateral hemisphere. Rats were euthanized by ttanscardial perfusion with 4% paraformaldehyde under Na-pentobarbital anesthesia, and fixed brains removed and cut into coronal cryostat sections. Adjacent serial sections through the striatum were then stained for: a) Malondialdehyde, using rabbit antiserum against malondialdehyde-modified protein (kindly provided by Dr. Craig Thomas, Hoechst Marion Roussel) 1:1,000. b) 8-iso-prostaglandin F2, using rabbit anti-8-iso-prostaglandin F2 (Assay Designs, Inc., Ann Arbor, MI) 1: 1,000. c) Heme oxygenase-1, using rabbit anti-heme oxygenase-1 (StiessGen, British Columbia, Canada) 1: 3,000. Results are shown in Figure 3 . Increased staining for all three markers were evident in rotenoneinjected striata, compared with vehicle-injected hemispheres in the same animals, both at 8h postinjection, and at 24. The pattern and approximate numbers of positively stained cells for each marker did not markedly differ between the two time points, suggesting that the maximal initial effect on oxidation may be achieved by 8 hours. Differences were apparent in the pattern and scope of staining with each of the markers. Malondialdehyde-positive cells were most prominent in the immediate vicinity of the lesion/injection site following rotenone. Cell morphologies suggest that most ceUs stained were neurons, but this must be verified by colocalizaion studies. Iso-prostaglandin F2 showed an intermediate level of staining, affecting more cells than malondialdehyde, over a larger area of stiiatum. Heme oxygenase-1 positive cells were the most abundant of all the markers examined. They were also present in the largest striatal volume. In addition, both glial and neuronal populations appear to stain positively for heme oxygenase-1.
We are currentiy performing co-localization studies to try to determine: a) whether specific neuronal populations are preferentially staining for these oxidation markers (eg. GAB A, ACh), and b) to confirm the neuronal and glial localization of these markers. We are also conducting experiments to elucidate the earliest time-point oxidative events can be detected, relative to the complex I inhibitory insult. Discussion: During the first eleven months of this study, a great deal of time has been taken up by training the research technicians in the techniques used in this project, namely stereotactic surgery, microdialysis (to be used in year 2), histology, and HPLC. We have also been optimizing dosing paradigms and complex I measurement techniques for these studies. However, initial results show that whilst low-grade complex I inhibiton is occurring shortly after rotenone introduction into rat striata, a rapid oxidative response is being elicited, and is detectable in these animals.
KEY RESEARCH ACCOMPLISHMENTS
• Demonstration of reductions in ATP generation in affected brain regions in symptomatic HD mice (R6/2 model).
• Demonstration of elevations in other key phosphorylated energy metabolites over the course of phenotype generation in the R6/2 HD mouse model -most notably phosphocreatine.
• Determination of the time course of alterations in high-energy phosphates, over the life-span of R6/2 HD mice.
• Assessment of cerebral respiratory rates in the Hdh9^" mutant moue model of HD -no alteration at a timepoint when cerebral glucose uptake is elevated (4 months of age).
• Assessment of ATP synthesis in the Hdh^'" mutant moue model of HD -trend to increase at a timepoint when cerebral glucose uptake is elevated (4 months of age).
• Elucidation of optimum dosing paradigms and complex I measurements in a rat rotenone intrastriatal-injection model of PD-Uke neurodegeneration.
• Elucidation of the time-line of complex I inhibition following rotenone injection.
• Demonstration of early elevations in Upid peroxidation markers (malondialdehyde and 8-isoprostaglandin F2) around the site of rotenone insult in rat striatum.
• Demonstration of early and extensive induction of the cell stress marker heme oxygenase 1, following rotenone insult in rat striatum. 
REPORTABLE OUTCOMES (May 2002-April 2003)
Manuscripts
CONCLUSIONS
The overall goals of this proposal were to gain insight into the roles of defects in CNS energy metabolism and oxidative stress in mechanisms of neuronal death and dysfunction in neurodegenerative disorders. Outcomes may impact therapeutic strategies for treatment of both degenerative disorders and neurotoxin exposure. Previous studies in human and animal models have implicated the involvement of mis-metabolism and oxidative damage in the pathogenesis of several neurodegenerative diseases including Parkinson's disease (PD). This project concentrated largely on using in vivo techniques in whole animal models of degenerative disorders, to gain insight into disease mechanisms at all stages of pathogenesis.
In the first three years of this grant we made substantial progress in characterizing the nature of changes in cerebral energy metaboUsm seen in theR6/2, N171-82Q and Hdh mouse models of HD, both in vivo and in vitro. We have also shown that cerebral glucose metabolism is impaired in the G93A transgenic mouse model of FALS (overexpressing human mutant SODl) at 60 days of age, and ATP generation is depressed as early as 30 days. Our observations suggest that energetic dysfunction may play an intrinsic role in the pathogenesis of the motor neuron disorder seen in both HD and ALS mouse models, since alterations precede symptomatic and pathological changes in these animals.
In the period of this grant report, we have provided further evidence of metabolic compromise in the R6/2 mouse model of HD (reduced ATP levels in symptomatic mice, and alterations in high energy phosphates around the time of the first symptoms). We have also begun to address the interrelationship between energetic defects and oxidative damage in the context of another degenerative disorder, PD. Again using in vivo approaches, we have made progress towards optimizing experimental conditions for assessing the temporal association between inhibiting complex I activity at specific mitochondrial subunit sites, and producing free radicals and hence oxidative damage. While experiments still need to be fine-tuned, we have novel and tantalizing data showing the induction of oxidative damage to lipids, and the induction of the cell stiress-responder heme oxygenase-1, at a time point shortly after complex I inhibition. These observations have not been reported before, and in future experiments will be explored further to determine in vivo how rapidly oxidative damage occurs.
